Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Novartis said that its experimental complement inhibitor iptacopan reduced the buildup of protein in the urine of patients with IgA nephropathy significantly more than a placebo, and now the Swiss pharma company plans to apply for accelerated approval with th…